NASDAQ:ENSC Ensysce Biosciences Q1 2025 Earnings Report $3.05 +0.12 (+4.10%) Closing price 04:00 PM EasternExtended Trading$3.01 -0.04 (-1.31%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History Ensysce Biosciences EPS ResultsActual EPSN/AConsensus EPS -$3.02Beat/MissN/AOne Year Ago EPSN/AEnsysce Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEnsysce Biosciences Announcement DetailsQuarterQ1 2025Date5/9/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Ensysce Biosciences Earnings HeadlinesEnsysce Biosciences secures patent for OUD treatmentApril 26 at 12:20 AM | uk.investing.comEnsysce Biosciences receives U.S. patent for OUD treatmentApril 25, 2025 | markets.businessinsider.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 29, 2025 | Porter & Company (Ad)Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross ProceedsApril 23, 2025 | gurufocus.comEnsysce Biosciences Stock Doubles In One Trading Session - Here's WhyApril 23, 2025 | benzinga.comEnsysce Biosciences announces data from opioid overdose protection studyApril 17, 2025 | markets.businessinsider.comSee More Ensysce Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ensysce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ensysce Biosciences and other key companies, straight to your email. Email Address About Ensysce BiosciencesEnsysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.View Ensysce Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Upcoming Earnings Automatic Data Processing (4/30/2025)Equinix (4/30/2025)KLA (4/30/2025)Meta Platforms (4/30/2025)Microsoft (4/30/2025)QUALCOMM (4/30/2025)Aflac (4/30/2025)Allstate (4/30/2025)Caterpillar (4/30/2025)Canadian Pacific Kansas City (4/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
